Showing results (2711-2720 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 13, 2025
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditisZhaoquan Wu, Wei Sun, Chunjiang Wang
Investigational New Drugs|August 20, 2021
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung diseaseSatoshi Igawa, Masanori Yokoba, Akira Takakura, et al.
Investigational New Drugs|August 21, 2021
Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designsTakehiro Hirai, Asuka Suzuki, Takao Yamori, et al.
Investigational New Drugs|December 1, 1987
Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivoS D Harrison, R W Brockman, M W Trader, et al.
Investigational New Drugs|December 1, 1987
In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assayY Sasaki, F Kanzawa, H Takahashi, et al.
Investigational New Drugs|December 1, 1987
Brain uptake and CNS levels of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (HECNU)C Unger, H Eibl, J Engel, et al.
Investigational New Drugs|June 12, 2020
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumorsCharlotte Lemech, Natasha Woodward, Nancy Chan, et al.
Investigational New Drugs|July 5, 2025
The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcomaNawfal Yousif Jamil, Mohammed S Nawrooz, Ashok Kumar Bishoyi, et al.
Investigational New Drugs|July 27, 2025
Clinical features, treatment and outcomes of dabrafenib-associated uveitisJieqiong Liu, Wei Sun, Chunjiang Wang
Investigational New Drugs|July 24, 2025
Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancerYuehong Zhu, Yaoyang Guo, Ziyi Dong, et al.
Pageof 372